29 results
Thumbnail

D1.01 - Anaphylaxis After Crayfish Consumption with Strong Anisakis simplex Sensitization

Thumbnail

D1.13 - A rare case of isolated histaminergic angioedema

Thumbnail

D1.15 - True Mugwort Sensitization Presenting as Severe Atopic Dermatitis: A Diagnostic Challenge

Thumbnail

D1.02 - Sensitization to Sesame Proteins Despite Negative Conventional Testing

Thumbnail

D1.03 - Identification of a Thaumatin-Like Protein as a Shared Allergen in Kiwi and Persimmon: Molecular Analysis in a Case of Anaphylaxis

Thumbnail

D1.05 - IgE-Mediated Rice Allergy: The Role of Immunoblotting in Allergen Identification

Thumbnail

D1.07 - Risk Stratification Tools in Suspected Beta-Lactam Allergy: A RealLife Delabeling Study

Thumbnail

D1.08 - Clinical relevance of troponin C (Cra c 6) sensitization in crustacean allergy

Thumbnail

D1.09 - Mast cell disorders in children with food-induced anaphylaxis

Thumbnail

D1.10 - Underrecognition of Anaphylaxis in Children: Gaps in Diagnosis and Management

Thumbnail

D1.11 - Determinants of allergen sensitization and wheal size variability in skin prick testing in a large outpatient cohort

Thumbnail

D1.12 - Cross-Reactivity Between Peach Juice and Cupressaceae Pollen

Thumbnail

D1.14 - Biphasic, Refractory, and Persistent Anaphylaxis in Children

Thumbnail

D1.06 - When an alergic reaction turns into a cardiac event: clinical characterization of Kounis Syndrome

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis